Population pharmacokinetic and exposure –response analyses of elotuzumab plus pomalidomide and dexamethasone for relapsed and refractory multiple myeloma

ConclusionsThe PPK model adequately described the data and was appropriate for determining exposures for exposure –response analyses. There were no clinically relevant differences in elotuzumab exposures between Pd and Ld backbones. In ELOQUENT-3, increasing elotuzumab daily Cavg prolonged PFS without increasing grade 3  + AEs.
Source: Cancer Chemotherapy and Pharmacology - Category: Cancer & Oncology Source Type: research